Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor

Cardiology

Volumn 117, Issue 3, 2011, Pages 231-233

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Arrhythmia; Heart failure; Mortality; Ticagrelor

Indexed keywords

ADENOSINE; CLOPIDOGREL; PRASUGREL; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; CAUSE OF DEATH; DRUG MECHANISM; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; LOADING DRUG DOSE; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SEPSIS; SUDDEN DEATH; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 78650869896     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322789     Document Type: Review

References (21)

1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; the PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
2. Ticagrelor Secondary Review. www.fda.gov/ downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM220192.pdf
3. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G: Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990; 82: 17-26.
4. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S; CURRENT-OASIS 7 Investigators: Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942.
5. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; the TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
6. VAN Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ: Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009; 7: 1556-1565.
7. Serebruany VL: Adenosine release: a potential explanation for the benefits of ticagrelor in PLATO? Am Heart J 2010, in press.
8. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
9. Linden J: Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol 2001; 41: 775-787.
10. ISIS-2 Trial Investigators: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-360.
11. COMMIT Collaborative Group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-1621.
12. Malkin CJ, Channer KS: Life-saving or lifeprolonging? Interpreting trial data and survival curves for patients with congestive heart failure. Eur J Heart Fail 2005; 7: 143-148.
13. Cohen MV, Downey JM: Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 2008; 103: 203-215.
14. Headrick JP, Lasley RD: Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol 2009; 193: 189-214.
15. Yildiz G, Demiryürek AT, Gümüel B, Lippton H: Ischemic preconditioning modulates ischemia-reperfusion injury in the rat lung: role of adenosine receptors. Eur J Pharmacol 2007; 556: 144-150.
16. Germack R, Dickenson JM: Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005; 39: 429-442.
17. Narayan P, Mentzer RM Jr, Lasley RD: Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes. J Mol Cell Cardiol 2001; 33: 121-129.
18. Sadigh B, Shahgaldi K, Sylvén C, Quintana M, Winter R: Preconditioning effects of adenosine in patients with severe coronary artery disease but preserved coronary flow reserve. Cor Artery Dis 2009; 20: 354-359.
19. Canyon SJ, Dobson GP: Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am J Physiol Heart Circ Physiol 2004; 287:H1286-H1295.
20. Riccardi A, Arboscello E, Ghinatti M, Minuto P, Lerza R: Adenosine in the treatment of supraventricular tachycardia: 5 years of experience (2002-2006). Am J Emerg Med 2008; 26: 879-882.
21. Fredholm BB: Adenosine receptors as drug targets. Exp Cell Res 2010; 316: 1284-1288.